Cirmtuzumab (also UC-961) is an anti-ROR1 humanised monoclonal antibody. It is an experimental drug in early-stage clinical trials for various cancers...
3 KB (135 words) - 09:07, 18 August 2023
Emergency Use Authorization (EUA) when used with tixagevimab COVID-19 Cirmtuzumab humanized ROR1 chronic lymphocytic leukemia Citatuzumab bogatox Fab humanized...
135 KB (4,054 words) - 22:35, 2 July 2024
Thomas Kipps, discoverer of ROR1, and contributed to the development of cirmtuzumab Don W. Cleveland Marilyn Farquhar Napoleone Ferrara Quyen T. Nguyen "UC...
4 KB (329 words) - 05:50, 19 June 2024
discovery of a potential treatment for chronic lymphomatic leukemia called Cirmtuzumab. The health system coordinates its activities closely with the UC San...
27 KB (2,573 words) - 02:20, 31 July 2024
mertansine§ Brontictuzumab§ Cantuzumab mertansine§ Cantuzumab ravtansine§ Cirmtuzumab Citatuzumab bogatox§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab§...
5 KB (368 words) - 23:51, 17 July 2024
mertansine§ Brontictuzumab§ Cantuzumab mertansine§ Cantuzumab ravtansine§ Cirmtuzumab Citatuzumab bogatox§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab§...
3 KB (129 words) - 01:04, 19 July 2023
mertansine§ Brontictuzumab§ Cantuzumab mertansine§ Cantuzumab ravtansine§ Cirmtuzumab Citatuzumab bogatox§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab§...
4 KB (241 words) - 13:42, 14 July 2024